Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | F3 | P13726 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23609342 | 0.80 | LMNA (0.46) | — | |
| SCHEMBL1348506 | 0.73 | OPRM1 (0.42) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL28667688 | 0.73 | FAAH (0.66) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL16118345 | 0.73 | FAAH (0.76) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL1786409 | 0.73 | ALDH1A1 (0.54) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10425208 | 0.72 | SYK (0.51) | EPHX2 | |
| SCHEMBL7113709 | 0.72 | LRRK2 (0.50) | LRRK2CSF1RFLT1FLT3 | |
| SCHEMBL1785732 | 0.71 | OPRM1 (0.47) | FAAHHDAC6 | |
| SCHEMBL31557872 | 0.71 | PARP14 (0.61) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL31557918 | 0.71 | ROCK2 (0.49) | FAAHTRPA1EPHX2FAAH2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | claimed |
| US-8063247-B2 | Bicyclic aryl and heteroaryl receptor modulators | PROSIDION LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | PROSIDION LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267780-A1 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | FAAH 224/4885TRPA1 312/4885EPHX2 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.